+1 858-523-8231
Login | Register
AA Blocks, Building Blocks, Catalysts, Inhibitors
Login | Register
Home Other Building Blocks 1799711-21-9
1799711-21-9,MFCD31544503
Catalog No.:AA00ASB3

1799711-21-9 | dBET1

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
99%
in stock  
$62.00   $43.00
- +
5mg
≥98%
in stock  
$276.00   $193.00
- +
10mg
98% by HPLC
in stock  
$444.00   $311.00
- +
100mg
98%
in stock  
$544.00   $381.00
- +
250mg
98%
in stock  
$876.00   $613.00
- +
1g
98%
in stock  
$2,472.00   $1,731.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
Technical Information
Catalog Number:
AA00ASB3
Chemical Name:
dBET1
CAS Number:
1799711-21-9
Molecular Formula:
C38H37ClN8O7S
Molecular Weight:
785.2678
MDL Number:
MFCD31544503
SMILES:
O=C(COc1cccc2c1C(=O)N(C2=O)C1CCC(=O)NC1=O)NCCCCNC(=O)C[C@@H]1N=C(c2ccc(cc2)Cl)c2c(n3c1nnc3C)sc(c2C)C
Properties
Computed Properties
 
Complexity:
1550  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
1  
Heavy Atom Count:
55  
Hydrogen Bond Acceptor Count:
11  
Hydrogen Bond Donor Count:
3  
Rotatable Bond Count:
12  
Undefined Atom Stereocenter Count:
1  
XLogP3:
3.2  

Downstream Synthesis Route
1268524-70-4   
2-{4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno3,2-f1,2,4triazolo4,3-a1,4diazepin-6-yl}-N-4-(2-2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yloxy}acetamido)butylacetamide 

[1]Patent:WO2017/24317,2017,A2

[2]Synlett,2017,vol.28,p.2881-2885

[3]Synlett,2017,vol.28,p.2881-2885

[4]Patent:US2016/176916,2016,A1

[5]Patent:WO2018/148440,2018,A1

[6]Patent:WO2018/148443,2018,A1

[7]JournaloftheAmericanChemicalSociety,2019,vol.141,p.18370-18374

[1]CurrentPatentAssignee:DANA-FARBERCANCERINSTITUTE-WO2018/148440,2018,A1Locationinpatent:Page/Pagecolumn316;317

[2]CurrentPatentAssignee:DANA-FARBERCANCERINSTITUTE-WO2018/148443,2018,A1Locationinpatent:Page/Pagecolumn298

[3]CurrentPatentAssignee:DANA-FARBERCANCERINSTITUTE-US2016/176916,2016,A1Locationinpatent:Paragraph0107;0610

[1]CurrentPatentAssignee:DANA-FARBERCANCERINSTITUTE-WO2017/24317,2017,A2Locationinpatent:Page/Pagecolumn235-236

[1]Papatzimas,JamesW.;Gorobets,Evgueni;Brownsey,DuncanK.;Maity,Ranjan;Bahlis,NizarJ.;Derksen,DarrenJ.[Synlett,2017,vol.28,#20,p.2881-2885]

[1]Papatzimas,JamesW.;Gorobets,Evgueni;Brownsey,DuncanK.;Maity,Ranjan;Bahlis,NizarJ.;Derksen,DarrenJ.[Synlett,2017,vol.28,#20,p.2881-2885]

Literature

Title: Winter GE, et al. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science. 2015 Jun 19;348(6241):1376-81.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 1799711-21-9
1818885-28-7

1818885-28-7

 1950634-92-0

1950634-92-0

 1883863-52-2

1883863-52-2

 1957234-97-7

1957234-97-7
Building Blocks
More >
Tags:1799711-21-9 Molecular Formula|1799711-21-9 MDL|1799711-21-9 SMILES|1799711-21-9 dBET1